Found an article today talking about Samumed, I'll try and post a link, but last time I tried it wouldn't let me! Quote below for the part that peeked my interest.
http://magazine.pomona.edu/2016/fall/how-to-build-a-fountain-of-youth-piece-by-piece/
'The FDA is the gatekeeper, and though less than 10% of proposed new drugs ultimately earn FDA approval, the likelihood increases with each step forward in the lengthy process. The next step for Samumed’s most advanced projects, the hair loss and osteoarthritis drugs, is large Phase III studies with thousands of participants. Some 64% of drugs that begin Phase III studies are submitted for FDA approval and 90% of those are successful, according to a study cited by the independent site
fdareview.org.'
Might not mean anything cause the next logical step is a phase III and they're just assuming here, but it was only posted on the 25th, the same day as the release Samumed put out, so maybe there's something.
For those that can't see the original link:
'October 25, 2016 Samumed Successfully Completes a Phase II Androgenetic Alopecia (“Androgenetic Alopecia”) Biopsy Trial Studying Regeneration of Hair Follicles San Diego, CA – Samumed, LLC successfully completed a 135-day study of its topical compound, SM04554, on 49 male subjects with Androgenetic Alopecia analyzed by biopsy of the scalp prior to and post dosing. The safety and the efficacy results of this second Phase II Trial further support the safety and efficacy findings from the company’s prior trials. Moreover, the biopsy results support the program’s mechanism-of-action regarding new hair follicle regeneration. As the Company previously reported, efficacy data from its first Phase II Androgenetic Alopecia trial showed statistically significant increases for both objective outcome measures: non‐vellus hair count (a primary outcome measure) and hair density (a secondary outcome measure), using the pre‐specified statistical model. Further, in that first Phase II Androgenetic Alopecia study, there were no serious adverse events observed in any treated patient, and the incidence of adverse events was similar between treatment and vehicle groups. The Phase II Androgenetic Alopecia Biopsy study results will be presented at upcoming medical conferences.'